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in the IMT group accord with the CONSORT2 guide-
lines?
In their introduction, they comment that `` many
pharmacological treatments have been tried for IC
though without major benefit'', however, Beebe,
et al.,3 discussed the doubling of MWD obtained at
24 weeks with Cilostazol. In their study, the authors
reported that IMT only improved MWD by a half ± a
result that was not statistically significant. But in their
conclusions they state that the increases in walking
distance with IMT are significant and that it is an
effective treatment for patients with IC. However,
taking p5 0.05 as the level of significance for their
primary end point there was no statistically signi-
ficant difference between the two groups in terms of
number of responders, or improvement to MWD.
Furthermore, the lack of benefit obtained in this
study with IMT or placebo to increase MWD (50 and
30% respectively) should be contrasted to the 122%
increase in MWD that is seen with supervised
exercise training as reported in the meta-analysis by
Gardner et al.4
The authors have also been positively selective in
their interpretation of data in the literature regarding
IMT; several of their references relate to abstracts and
the paper by Cooke et al.5 showed that there was no
statistically significant improvement in blood flow
parameters with IMT.
Could the authors provide details as to the homo-
geneity of the two groups during the study? E.g. How
many patients in each group changed their smoking
habits, cholesterol and antihypertensive medication,
exercise habits, diet, or body weight during the
6-month period of study, all of which could have
influenced the results independently of the IMT
received? Small changes in body weight for example
candramatically influencewalking distance.6 Although
the authors report a change in quality of life (QOL)
during the study, we would be grateful to know what
the baseline QOL domain scores were in each group
and whether they were the same in both groups?
The generalizability of these results to the general
population of claudicants seen in hospital is uncertain.
Did randomisation follow the COSORT2 guidelines?
Only 46 claudicants were recruited by each centre
over a period of 28 months which suggests that either
a great deal of patients were deemed not suitable for
inclusion or that there was a process of selection. The
adequacy of randomization is also difficult to ascer-
tain from the details provided in the paper. The treat-
ment to which the patient was randomized should
ideally be implemented by using allocation conceal-
ment to prevent prior knowledge of treatment assign-
ment. This shields those who enrol participants from
being influenced by this knowledge. The decision to
enrol or reject a patient should be made, and informed
consent should be obtained from the participant, in
ignorance of the next assignment in the sequence.
E. P. L. Turton, D. J. A. Scott and
S. R. Carding
St. James's University Hospital,
Leeds, U.K.School of Molecular Biology and Immunology,
University of Leeds
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Correspondence 467We thank Mr Turton and colleagues for their interest
in our study. Taking their points in turn:
Huge placebo response
We acknowledge that the immediate response seen
here in the placebo group is high, although to charac-
terise it as huge is to overstate the case. Placebo
responses as high as 36% have been reported in trials
of Pentoxifylline.1 Additionally, in a study comparing
Beraprost sodium to placebo, Michel Lievre et al.
reported that 42.2% of patients in the placebo groupEur J Vasc Endovasc Surg Vol 24, November 2002
468 Correspondencehad a 4 50% improvement in ICD on treadmill exer-
cise at 6 months, a figure almost identical to that seen
here.2 It is a common first reaction to think that IMT
will be painful, but analysis of pain-related adverse
events reported in this study and clinical experience
has shown this not to be the case.
Choice of placebo
The choice of placebo was considered carefully when
the study was planned. As the effect and safety of
injections with untreated blood are not known, we
preferred to use saline, an inert preparation.
Frequency of injections
Administering further injections dependent on
response was a fundamental part of the study design
and we naturally informed patients during the con-
sent process. It would have been unethical not to do
so. Similarly patients were informed that a 50%
increase in ICD from baseline would be the trigger to
cease treatment.
Changes in lifestyle
We tried to monitor this as Mr Turton and colleagues
correctly suggest that changes in life-style may have
affected the results. During the study cholesterol
levels and medications remained unaltered. Exercise
and weight change were not captured and this may be
a confounding factor. Change in smoking habit was
recorded. One patient in each group ceased, whilst
two in the IMT group and four in the placebo group
reported a decrease in smoking.
Quality of life
A table with the full results is available from the
authors on request. With the exception of Physical
Functioning there were no significant differences
between groups in the QOL domains. In the Physical
Functioning domain the baseline median score in the
placebo group was 35 (IQR 30±50) compared to
50 (IQR 35±60) in the IMT group (p 0.037, Mann±
Whitney U-test). At study end, whilst the scores in
this domain improved in both groups, the placebo
group improved such that there was no significant
difference between groups.
Recruitment rate
The small number of patients recruited in both centres
over the time period was comparable and most likely
reflects the strict inclusion/exclusion criteria consid-
ered necessary for the first study of this kind. Add-
itionally, it is possible more patients than usual may
have declined to participate due to the invasiveness ofEur J Vasc Endovasc Surg Vol 24, November 2002the study. In accordance with ICH GCP guidelines
data on non-consented patients was not collected.
Randomisation
The revised CONSORT statement to which Mr Turton
refers was not available at the time of designing this
study. However, the system used for randomisation
was chosen carefully and does comply with the guide-
lines. The Contract Research Organisation managing
the study computer-generated the randomisation
sequence. Each random assignment was allocated
a study number in chronological order and this infor-
mation concealed from the `` blinded'' investigator.
Eligible patients were assigned the next available
study number by the `` blinded'' investigator. At the
first treatment visit the `` unblinded'' investigator
referred to the randomisation assignment and treated
the patients as allocated.
Study design
As this was a feasibility study, the effect of IMT on IC
was examined as well as the number of treatments
necessary to see an effect. An increase in ICD of
450% was chosen as the primary end-point from the
outset as it was deemed to be a clinically relevant
response and had been used previously.2,3 Statistical
advice was sought during the analysis and whilst the
methodology used may not comply precisely with the
CONSORT guidelines they were considered most
appropriate for the design of the study.
Cilostazol trials
We acknowledged that clinical trials of Cilostazol have
led to US Food and Drug Administration (FDA)
approval.
To conclude, this study is the first randomised
double-blind controlled trial of a new treatment for
IC. Despite small numbers, symptomatic improve-
ment was seen and correlated with improvements in
quality of life. Finally, this work has already lead to
FDA approval to conduct a 500 patient multi-centre
clinical trial in North America.
C. McGrath, R. Robb, A. J. Lucas, A. H. R. Stewart,
C. L. Underwood, J. K. Horridge, P. M. Lamont,
F. C. T. Smith, R. N. Baird and J. J. Belch
Bristol and Dundee, U.K.
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Compartment Syndrome
Sir,
We read with interest the case report of Reddy et al.1
This highlights arm compartment syndrome due to
puncture of an arterio-venous fistula in a patient
who was subsequently found to be excessively hepar-
inised. We would like to emphasise three points that
relate to forearm compartment syndrome. Firstly the
important symptoms for diagnosing compartment
syndrome are pain (especially out of proportion to
the injury) and paraesthesia.2 The paraesthesia is
especially important in these patients, as loss of two-
point discrimination occurs early and is an extremely
sensitive sign for diagnosing the condition. The
authors have described paraesthesia but the character
and method of assessment has not been defined.
The second point to note is that a clinical diagnosis
of compartment syndrome was made in this patient
because of the classical clinical symptoms and in these
patients there is no need for intra-compartmental
pressure measurement. The good result obtained in
this case was likely to be due to undergoing decom-
pression within 12 h but this has also not been
mentioned. The final point to note is the risk of com-
partment syndrome as a hazard of puncture of any
blood vessel in any anticoagulated patient. It is these
patients in whom pain in the arm following such a
procedure should not, necessarily, be to be blamed on
the trauma caused by the actual puncture but may
also be caused due to intra-compartmental bleeding.
A. Tiwari, F. Myint, G. Hamilton
Royal Free Hospital, London, U.K.
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Carotid Endarterectomy
Sir,
This article by Wijeyaratne et al.1 discusses a sound
technique for the removal of intact carotid endarter-
ectomy specimens and makes clear the implications
for research and quality control.
The authors state that the method is particularly
useful in those not requiring a shunt and that in
those that require shunting the shunt may be inserted
after plaque removal, which takes 2±3 min. However,
in our experience the endarterectomy procedure may
take a longer than 3 min. Careful dissection is needed
for all plaques if suitable specimens are to be obtained
and some plaques may require prolonged dissection
to ensure a smooth luminal surface is left following
endarterectomy. If this phase of the procedure is
lengthy and the patient requires a shunt this clearly
increases the risk of cerebral hypoperfusion. If patients
requiring a shunt are excluded from research or qual-
ity control analysis then an important subgroup of
patients (such as those with high-grade stenoses or
highly inflamed plaques) may be unintentionally
missed.
Shunting is possible during plaque dissection by
making a second arteriotomy at the distal extent of
the plaque within the ICA after the adventitia is
divided with Pott's scissors. This allows the shunt to
be placed prior to plaque removal, which can be carried
out in a controlled, careful fashion. Figure 1 illustrates
Fig. 1. Proximal and distal arteriotomy to allow shunt placement
without damaging the endarterectomy specimen.
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